Search tips
Search criteria 


Logo of eukcellPermissionsJournals.ASM.orgJournalEC ArticleJournal InfoAuthorsReviewers
Eukaryot Cell. 2005 January; 4(1): 63–71.
PMCID: PMC544169

Tor and Cyclic AMP-Protein Kinase A: Two Parallel Pathways Regulating Expression of Genes Required for Cell Growth


In the budding yeast Saccharomyces cerevisiae, the Tor and cyclic AMP-protein kinase A (cAMP-PKA) signaling cascades respond to nutrients and regulate coordinately the expression of genes required for cell growth, including ribosomal protein (RP) and stress-responsive (STRE) genes. The inhibition of Tor signaling by rapamycin results in repression of the RP genes and induction of the STRE genes. Mutations that hyperactivate PKA signaling confer resistance to rapamycin and suppress the repression of RP genes imposed by rapamycin. By contrast, partial inactivation of PKA confers rapamycin hypersensitivity but only modestly affects RP gene expression. Complete inactivation of PKA impairs RP gene expression and concomitantly enhances STRE gene expression; remarkably, this altered transcriptional pattern is still sensitive to rapamycin and thus subject to Tor control. These findings illustrate how the Tor and cAMP-PKA signaling pathways respond to nutrient signals to govern gene expression required for cell growth via two parallel routes, and they have broad implication for our understanding of analogous regulatory networks in normal and neoplastic mammalian cells.

The Tor kinases are central components of a signal transduction cascade primarily associated with linking amino acid and growth factor availability to translational control in organisms as diverse as flies, nematodes, and humans (reviewed in references 18, 28, and 38). Recent studies have shown that this is also the case for the yeast Saccharomyces cerevisiae, in which Tor interacts, via TAP42 and the type 2A related protein phosphatase (PP2A) Sit4, with the general amino acid control response to regulate translation (9, 26, 42, 59).

The Tor kinases are also the targets of the antiproliferative drug rapamycin. The high specificity of rapamycin to inhibit Tor activity has facilitated the dissection of the transcriptional programs regulated by Tor signaling. Inhibition of Tor by rapamycin induces genes required for utilization of poor-quality nutrients and adaptation to environmental stress and concomitantly represses genes that promote growth, such as those involved in ribosome biogenesis (2, 7, 20, 25, 37). Under rich nutrient conditions, Tor activity represses the expression of the nitrogen catabolite-repressed (NCR), retrograde response (RTG), and stress-responsive (STRE) genes. Concomitantly, Tor activity sustains the expression of genes required for ribosome biogenesis, including the ribosomal protein (RP) genes (reviewed in references 41 and 43). Control of Tor-repressed, rapamycin-inducible genes is exerted by alterations in the phosphorylation state and thereby the nuclear import of the corresponding transcription factors.

Less is known about the mechanisms by which Tor regulates RP gene expression; however, it is known that this mechanism does not involve Sit4 (11, 42). Coordinate expression of RP genes is associated with recruitment of the NuA4 histone acetylase catalytic subunit Esa1 to the promoters of these genes (39). RP gene expression is thought to be largely controlled by the Rap1 and Abf1 transcription factors (for reviews, see references 61 and 62). We have shown previously that Tor signaling recruits the Esa1 histone acetylase to RP gene promoters without affecting Rap1 or Abf1 promoter occupancy (44).

The extraordinary diversity of genes that are affected by Tor signaling implies that, in almost every case, these genes are also regulated by other signal transduction cascades. A major question, then, is how the Tor pathway interacts with these other pathways to regulate common gene targets. Tor and cyclic AMP-protein kinase A (cAMP-PKA) are two prominent, evolutionarily conserved signal transduction cascades that couple nitrogen and carbon source availability, respectively, to regulate diverse cell responses that ultimately drive cell growth and proliferation. Remarkably, Tor and the cAMP-PKA pathways control a number of common functions, including ribosome biogenesis and responses to stress. In addition, Tor and PKA signaling converge on the Rim15 kinase to control distinct transcriptional and metabolic traits required for proper entry into Go, a key developmental transition in yeast (36). Given these myriad functions, it is not surprising that these pathways converge to regulate the expression of a panoply of genes, such as the RP and STRE genes and the Gcn4-regulated genes that are involved in amino acid metabolism (2, 7, 16, 17, 24, 32, 34, 37). Evidence has been presented recently to suggest that the Tor pathway might even signal via the PKA pathway to control several functions, including RP gene expression (47).

In S. cerevisiae, the PKA pathway responds to glucose and regulates resistance to stress, glycolysis, and gluconeogenesis. PKA is composed of a regulatory subunit encoded by the BCY1 gene and three catalytic subunits encoded by the TPK1, TPK2, and TPK3 genes (6, 55, 56). In resting cells, PKA is an inactive tetramer consisting of two regulatory subunits in complex with two catalytic subunits. In response to external signals, such as glucose, adenylyl cyclase is activated, cAMP levels rise, and cAMP binding to the PKA regulatory subunit triggers conformational changes that release the PKA catalytic subunits in an active form. Adenylyl cyclase is activated via two independent glucose-sensing modules. In the first, the glucose receptor Gpr1 is coupled to the Gα protein Gpa2 and functions to activate cAMP production in response to ligand binding (for a review, see reference 19). In the second module, Ras1 and Ras2 function in conjunction with their positive regulators, the guanine nucleotide exchange factors Cdc25 and Scd25, to activate adenylyl cyclase in response to glucose and other unknown stimuli (33). The overexpression of a dominant active RAS2V19 allele results in increased levels of cAMP (57). Ras is also negatively regulated by the GTPase-activating proteins (GAP) Ira1 and Ira2 (52), and the levels of cAMP and PKA activity are negatively controlled by the cAMP phosphodiesterases Pde1 and Pde2.

In this study, we have further investigated the interplay between the Tor and cAMP signaling cascades that regulate gene expression required for cell growth. Mutations that hyperactivate the cAMP-PKA pathway were found to render growth resistant to rapamycin and, moreover, to prevent rapamycin-induced repression of RP genes. However, RP gene expression is still sensitive to Tor signaling in strains that completely lack PKA activity or the PKA-related kinases Yak1 and Sch9. We conclude that the Tor and cAMP-PKA cascades function coordinately but independently of one another to govern appropriate RP gene expression. This regulatory network likely functions to provide cells flexibility in fine tuning translational capacity in response to distinct inputs from two global nutrient sensors.


Yeast strains and media.

Strains used in this study are listed in Table Table1.1. With the exceptions indicated below, all strains are isogenic derivatives of MLY41 (Σ1278b background) (30). Strains SGY73, SGY77, and ASY63 are derived from S288c and were kindly provided by Stephen Garrett. Yeast media were prepared as described previously (14, 48). Rapamycin was added to the media from concentrated stock solutions in 90% ethanol-10% Tween 20. Yeast transformations were performed by the lithium acetate method (46). Unless noted otherwise, mutant yeast strains were constructed by PCR-mediated gene disruption, replacing the entire open reading frame of the targeted gene with the G418 resistance gene cassette derived from template plasmid pFA6-kanMX2, the nourseothricin (nat) resistance gene cassette derived from plasmid pAG25, or the hygromycin B (hygB) resistance gene cassette derived from plasmid pAG32 (15, 29). All gene deletions were confirmed by PCR. Strain SZY9 was constructed by crossing SZY6 to XPY14-1. The resulting diploid was sporulated, and the progeny were dissected and genotypes were verified by PCR analysis. Loss of plasmid pXP1 (containing the BCY1 gene) from strain XPY26 was selected on 5-fluoroorotic acid medium. Plasmids pRS316 (CEN URA3) and pMW2 (CEN URA3 RAS2V19) were previously described (49, 60).

Yeast strains

Northern blotting.

RNA isolation and Northern blot analysis were performed as described previously (7). DNA probes hybridizing to RPS26, RPS28B, ACT1, MEP2, GAP1, CIT2, and SOD2 genes were PCR amplified from yeast genomic DNA with specific primers. Signals were quantified with a Typhoon 9200 variable mode imager by using Image Quantifier 5.2 software (Molecular Dynamics).

cAMP assay.

Cell cultures were grown to exponential phase in yeast extract-peptone (YP)-glucose medium, harvested, washed three times in YP medium, transferred to YP medium, and incubated for 2 h to deplete glucose. Cell cultures were divided in two, the cultures were treated with 50 nM rapamycin or drug vehicle alone, and incubation was continued for 15 min. Cell aliquots were removed at 0 (no glucose), 0.5, 1, and 3 min after the addition of 2% glucose, and cAMP was determined as described earlier (23).

Glycogen staining.

Exponentially growing cells were treated with 100 nM rapamycin and incubated at 30°C. After 4 h of treatment, samples containing 5 optical densities of cells were harvested on Millipore HA filters and exposed to iodine vapors for 2 min.


Mutations that activate the PKA pathway confer resistance to rapamycin and largely prevent rapamycin-induced inactivation of RP genes.

The Tor and cAMP-PKA signaling cascades are known to regulate the expression of RP genes in response to nutrients; in this study, we sought to determine whether the two pathways signal via independent or interdependent mechanisms to execute this function. To establish if the PKA pathway is linked to Tor signaling, we investigated whether mutations that activate PKA alter the sensitivity of cells to rapamycin. As shown in Fig. Fig.1A,1A, mutant strains lacking the Ras negative regulator Ira1, Ira1 and Ira2, or the PKA negative regulatory subunit Bcy1, are all more resistant to rapamycin than the wild-type strain. Similarly, the expression of the dominant activated RAS2V19 allele leads to increased rapamycin resistance.

FIG. 1.
Hyperactivating mutations of the PKA pathway confer resistance to rapamycin and prevent rapamycin-induced RP gene repression. (A) Isogenic wild-type (MLY41a), ira1 (THY337), ira2 (THY336), ira1 ira2 (THY345), and bcy1 (XPY26) mutants, wild-type strain ...

We have previously shown that the Rpd3 histone deacetylase operates at RP gene promoters and enables repression of RP genes in response to rapamycin. Accordingly, we found that Rpd3 was bound to RP genes, and mutations affecting three different Rpd3 subunits conferred resistance to rapamycin and partially prevented RP gene repression induced by rapamycin (44). Based on these observations and the known action of PKA in regulating RP genes, we reasoned that the PKA-activating mutations that increase rapamycin resistance do so by preventing RP gene repression. To test this hypothesis, we examined the expression of the RP genes and compared it to that of other Tor-regulated genes in the different PKA-activating mutant strains.

As shown previously, in wild-type cells RP gene transcripts decreased to almost undetectable levels within 1 h of treatment with rapamycin (Fig. (Fig.1B)1B) (7). Concomitantly, the expression of the NCR genes MEP2 and GAP1, and of the retrograde response gene CIT2 also known to be under Tor control, was rapidly induced after exposure to rapamycin (Fig. (Fig.1B).1B). It is known that both Tor and PKA activity antagonize induction of the general stress response genes regulated by Msn2 and Msn4 (2, 16, 17). Therefore, we examined the transcription levels of the SOD2 gene, which is induced by oxidative stress and nutrient deprivation. As expected, SOD2 was strongly induced in response to rapamycin (Fig. (Fig.1B1B).

In accord with previous studies, we found that expression of the RP genes was slightly increased in the different PKA-activated mutants compared to the wild-type strain (24). Interestingly, PKA activation by the bcy1 or ira1 ira2 mutations, and more prominently by expression of RAS2V19, partially prevented rapamycin-induced repression of the RP genes (Fig. 1B and C). The fact that in the ira1 ira2 and bcy1 mutants some RP gene expression was still responsive to Tor inhibition by rapamycin, although to a lesser magnitude than that observed with the wild-type strain, argues that the two pathways must be at least partially independent. The PKA-activating mutations impaired expression of the STRE gene SOD2 seen in response to rapamycin and did not have significant effects on the rapamycin-induced expression of the NCR or RTG-regulated genes analyzed in this study (Fig. (Fig.1B1B).

Our results show that mutations that activate the PKA pathway confer resistance to rapamycin, and this resistance correlates with the ability of these mutations to prevent rapamycin-induced repression of the RP genes. These results are in agreement with a recent study demonstrating that PKA activation overcomes rapamycin hypersensitivity conferred by mutation of Gln3 and prevents RP gene repression (47).

Partial inactivation of the cAMP-PKA pathway confers rapamycin-hypersensitive growth and has modest effects on RP gene expression.

Next, we tested the effect of mutations that inactivate PKA signaling on Tor-regulated gene expression. Interestingly, deletion of any of the three PKA catalytic subunits resulted in hypersensitivity to rapamycin, and this effect was more marked in the tpk1 tpk2 double mutant strain. In addition, deletion of RAS2 or GPA2, which leads to defects in PKA activation, also conferred rapamycin hypersensitivity (Fig. (Fig.2A2A and data not shown).

FIG. 2.
Mutations that partially inactivate the cAMP-PKA pathway confer rapamycin-hypersensitive growth and impair RP gene expression. (A) Isogenic wild-type (MLY41a), ras2 (MLY187), tpk1 (XPY4-1), tpk2 (XPY5-1), tpk3 (XPY6-1), and tpk1 tpk3 (XPY14-1) mutant ...

We next analyzed whether the increased sensitivity to rapamycin of the PKA defective strains is correlated with changes in RP gene expression. Deletion of either RAS2 or GPA2 did not alter RP gene expression; however, strains with a deletion of the TPK1 gene alone or in combination with TPK2 or TPK3 showed decreased levels of RP gene expression compared to the wild-type strain (Fig. 2B and C; data not shown for GPA2). Moreover, the PKA-inactivating mutations had little impact on the rapamycin-induced repression of RP genes or on the induction of the GAP1, MEP2, CIT2, and SOD2 genes.

Ras-cAMP PKA and Sch9 appear to stimulate growth via parallel pathways, as hyperactivation of either signaling cascade suppresses loss of the other (54). To test if the Sch9 kinase might be involved in the PKA pathway, we tested whether Tor signals via Sch9 to regulate RP gene expression. We found that mutation of Sch9 had no effect on Tor-regulated RP gene expression (data not shown). These results do not support models in which Tor regulates RP gene expression via Ras2, Gpa2, a specific PKA catalytic subunit, or the Sch9 kinase. However, our results do not rule out a redundant role for the three TPK subunits in regulating RP gene expression downstream from Tor.

Tor signaling regulates RP gene expression by a PKA-independent mechanism.

To test whether there is redundancy between the three TPK subunits to regulate RP gene expression, we constructed a strain lacking all three subunits. Simultaneous deletion of all three PKA catalytic subunits is lethal (5). However, suppression of the stress response, either by mutation of Msn2 and Msn4 or by mutation of the PKA-related kinase Yak1, restores viability of tpk1 tpk2 tpk3 mutant cells (50). The tpk1 tpk2 tpk3 yak1 deletion strain exhibited slow growth when compared to either wild-type or the yak1 strain. In addition, the tpk1 tpk2 tpk3 yak1 mutant strain exhibited a dramatic hypersensitivity to rapamycin; the MIC at which 100% of the isolates are inhibited was 10 nM for this mutant strain, compared to >100 nM for the wild type (Fig. (Fig.3A).3A). For comparison, we also tested the effects of these PKA mutations in a different strain background. As shown in Fig. Fig.4A,4A, the yak1 single, tpk1 tpk2 tpk3 yak1 quadruple, and tpk1 tpk2 tpk3 msn2 msn4 quintuple mutant strains in the S288c genetic background showed rapamycin sensitivity patterns similar to those observed with the PKA mutant strains of the Σ1278b background (Fig. (Fig.3A3A).

FIG. 3.
PKA catalytic activity is not required for Tor regulation of RP genes. (A) Isogenic Σ1278b wild-type (MLY41), yak1 (SZY2), and tpk1 tpk2 tpk3 yak1 (SZY9) strains were serially diluted onto YP-glucose medium with or without 50 nM rapamycin, grown ...
FIG. 4.
PKA catalytic activity is not required for Tor regulation of RP genes. (A) Isogenic wild-type, yak1 (SGY73), tpk1 tpk2 tpk3 yak1 (SGY77), and tpk1 tpk2 tpk3 msn2 msn4 (ASY63) strains from the S288c genetic background were serially diluted onto YP-glucose ...

Deletion of the three TPK genes resulted in a marked reduction in RP gene expression compared with the wild-type strain or the yak1 mutant strain. Moreover, in the tpk1 tpk2 tpk3 yak1 mutant cells from the two different strain backgrounds, RP gene expression was still repressed by rapamycin and thus was responsive to Tor signaling (compare Fig. 3B and C with Fig. 4B and C). PKA mutation did not have any significant effect on the rapamycin-induced expression of the NCR gene MEP2. As expected, PKA deletion resulted in derepression of the stress response gene SOD2, and this derepressed level of expression was further increased by rapamycin treatment (Fig. (Fig.3B;3B; quantified in Fig. Fig.3D).3D). These results lend further support to an earlier model proposed by two previous reports indicating that while PKA activity regulates the nuclear import of Msn2 and Msn4, Tor signaling regulates their nuclear export in a PKA-independent fashion (11, 17). We conclude that the PKA catalytic subunits are not required for Tor regulation of either RP or STRE gene expression. Importantly, these studies also indicate that if Tor signaling acts via the cAMP-PKA pathway, the point of cross talk between these two pathways is not at the level of any of the PKA catalytic subunits.

Activated Ras signals via the PKA catalytic subunits to overcome RP gene repression in response to rapamycin.

To address whether Tor signaling intercepts the PKA pathway at a component upstream from the three TPK subunits, we first examined the possibility that Tor regulates cAMP levels. We found that rapamycin treatment did not have any effect on the increase of cAMP levels produced in response to glucose addition to glucose-starved, nitrogen-replete cells (Fig. (Fig.5A).5A). Next, we tested whether the expression of the RAS2V19 allele in the tpk1 tpk2 tpk3 yak1 mutant strain overcomes RP gene repression induced by rapamycin. As shown above, wild-type cells become resistant to rapamycin when they are transformed with the activated RAS2 allele. However, the RAS2V19 allele is unable to confer rapamycin-resistant growth to the tpk1 tpk2 tpk3 yak1 quadruple mutant strain (Fig. (Fig.5).5). Similarly, overexpression of RAS2V19 requires PKA catalytic activity to overcome the rapamycin-induced repression of the RP genes in the tpk1 tpk2 tpk3 yak1 mutant strain (Fig. 5C and D).

FIG. 5.
Rapamycin does not interfere with the ability of cells to synthesize cAMP in response to glucose. (A) A culture of the wild-type strain (MLY41) was grown in YP-glucose medium to exponential phase. The cells were washed with YP medium (no glucose), transferred ...

These data exclude models in which Tor controls the activity of either adenylyl cyclase or cAMP phosphodiesterases. These results also demonstrate that Ras2V19 signals via the TPK subunits to overcome rapamycin toxicity. Our results are consistent with a model in which the TPK subunits are not required for Tor-regulated RP gene expression. Moreover, these results do not support models in which Tor signals to a PKA component upstream of the TPK subunits.

Tor regulates glycogen accumulation via a PKA-independent mechanism.

It is well established that both the Tor and PKA pathways control glycogen homeostasis (1, 12, 21). In addition, data from our gene array expression analysis revealed that rapamycin treatment induces the expression of genes required for glycogen synthesis (Table (Table2)2) (7). This result is consistent with several reports indicating that a number of genes required for glycogen synthesis are regulated, at least in part, by the Tor-regulated Msn2 and Msn4 transactivators (45, 50). Recently, it was proposed that rapamycin-induced accumulation of glycogen is blocked by high levels of PKA activity, suggesting that Tor signals through the PKA pathway to regulate glycogen homeostasis (47).

Rapamycin induces expression of genes involved in glycogen accumulationa

We tested whether Tor signaling regulates glycogen synthesis in strains lacking PKA activity. As expected, we observed that the tpk1 tpk2 tpk3 yak1 mutant strain contains higher levels of glycogen than wild-type cells. Remarkably, after exposure to rapamycin the tpk1 tpk2 tpk3 yak1 mutant strain stained darker when exposed to iodine vapors, indicating an increase in glycogen levels (Fig. (Fig.6A).6A). We also tested glycogen accumulation in the presence of rapamycin in the PKA mutant strain from the S288c genetic background. We observed that tpk1 tpk2 tpk3 yak1 mutant cells in this background showed an increased level of glycogen and that this level increases further in response to rapamycin, as seen in the corresponding PKA mutants in Σ1278b (compare Fig. 6A and B). These results indicate that Tor regulates glycogen homeostasis via a PKA-independent mechanism. This conclusion is in accord with a previous report, which suggested that the Tor and PKA signaling pathways act independently since glycogen accumulation in rapamycin-treated cells is not inhibited by hyperactivation of the cAMP-PKA pathway (1).

FIG. 6.
Tor signaling regulates glycogen accumulation in mutant cells lacking PKA activity. (A) Isogenic wild-type (WT) strain MLY41 and the tpk1 tpk2 tpk3 yak1 (SZY9) strain and (B) isogenic wild-type strain S288c and the tpk1 tpk2 tpk3 yak1 (SGY77) mutant strain ...


Control of cell growth is a complex process governed by nutrient availability and growth factors that are sensed and transmitted by specialized signal transduction cascades. In many known examples, common pathway components can generate cross talk between different signal transduction cascades. However, despite this cross talk, specialization of these pathways can be restored further downstream in the pathway by coordinating inputs from other signaling cascades and targeting different molecular effectors. In other cases, signal transduction cascades work strictly independently of one another but converge upon common downstream targets.

The Tor signaling cascade often functions in parallel with the PKA pathway to regulate common biological processes. Both the Tor and the cAMP-PKA pathways act early in G1 phase to regulate growth, cell cycle progression, entry into Go, and pseudohyphal differentiation in S. cerevisiae (1, 4, 8, 10, 22, 27, 30, 36, 40, 53, 63).

Cell growth is dependent upon ribosome biogenesis and translation. It is well established that the cAMP-PKA pathway has a positive role in regulating the expression of genes required for cell growth, including the RP genes, while simultaneously down-regulating genes required for stress responses and carbohydrate storage. The advent of DNA microarray technology and its application to analyze genome-wide gene expression allowed this view to be expanded and has resulted in the characterization of the Tor pathway as a second global nutrient-sensing signal transduction cascade that regulates growth via several of the same gene families governed by the cAMP-PKA cascade (7, 20; reviewed in references 41 and 43).

Given the myriad functions shared by the Tor and cAMP-PKA cascades, we reasoned that there could be cross talk between these pathways to execute these biological functions. Remarkably, contrary to this expectation, we find no evidence supporting models in which Tor signals via the cAMP-PKA pathway. First, complete elimination of all PKA activity by deletion of the three Tpk catalytic subunits resulted in a substantial reduction in RP gene expression, yet this reduced level of expression was still sensitive to rapamycin and thus subject to Tor signaling. Second, we found that tpk1 tpk2 tpk3 yak1 mutant cells accumulate higher levels of glycogen than wild-type cells, and this level increased further upon exposure to rapamycin. Third, the ability of the activated RAS2V19 allele to confer rapamycin-resistant growth and to overcome rapamycin-induced RP gene repression was found to be dependent upon PKA catalytic activity. This result argues against models in which Tor acts on PKA components downstream of Ras and upstream of the Tpk catalytic subunits. Fourth, because rapamycin treatment does not block the ability of the cell to increase cAMP levels in response to glucose, we can exclude models in which Tor signaling activates Ras and thereby adenylyl cyclase or those in which Tor regulates the activity of cAMP phosphodiesterases. Taken together, these results are in accord with a model in which Tor and cAMP-PKA function as two parallel pathways to independently regulate molecular factors engaged in the expression of RP and STRE genes as well as genes required for glycogen accumulation. While the Tor pathway negatively regulates STRE genes through the Tap42-PP2A effector branch and induces RP genes by a Tap42-PP2A-independent mechanism, the cAMP-PKA cascade orchestrates control of both gene families via the Tpk catalytic subunits (11, 42). This model is also consistent with the epistasis observations in this and a previous study that hyperactivation of one pathway can compensate for a block in the other (47). Our findings are in accord with a recent study in which it was demonstrated that Tor and PKA act independently of each other to regulate the Rim15 protein kinase that controls entry into Go (36). Moreover, our model is also in line with the observation that while PKA activity prevents the nuclear import of the STRE gene transactivators Msn2 and Msn4, Tor signaling controls the nuclear export of these factors (11, 17).

Our results are in agreement with a recent study demonstrating that hyperactivation of the PKA pathway increases the rapamycin resistance of gln3 gat1 mutant cells but has no effect on wild-type cells of the JK93d genetic background (47). We observed that PKA hyperactivation confers rapamycin resistance to otherwise wild-type cells of the Σ1278b genetic background. It is known that under normal conditions, the Σ1278b strain has a hyperactive PKA pathway (51). This fact may explain in part why the Σ1278b strain is more resistant to rapamycin than strains from other genetic backgrounds, including JK93d (42), and may explain why PKA hyperactivation in Σ1278b cells can overcome rapamycin toxicity in otherwise wild-type cells. Recently, it was shown that inactivation of Tor by rapamycin triggers the nuclear localization of the Tpk1 catalytic subunit and the Yak1 kinase (47). This effect was taken as evidence to propose that Tor signals via the PKA pathway to control common effector targets (47). While the functional significance of this nuclear localization event is still not understood, deletion of Tpk1 alone or in combination with Tpk2 and/or Tpk3 in the context of the tpk1 tpk2 tpk3 yak1 and the tpk1 tpk2 tpk3 msn2 msn4 multiple mutant strains did not perturb Tor-regulated expression of the RP and STRE genes or of the genes required for glycogen accumulation in our studies. Our findings therefore support models in which Tor and PKA signal independently of each other and do not support a recent proposal that Tor signals via PKA (47).

A major challenge in the Tor field is to understand how Tor acts in concert with other signaling cascades. In the case of the response to amino acid deprivation, there is cross talk between the Tor and the general amino acid control response pathways from the Tap42-Sit4 effector branch to the Gcn2 kinase and eIF2α (9, 26, 42). Here, we show that in contrast, Tor and the cAMP-PKA pathways act in parallel and converge to globally control the expression of genes involved in tuning the translational capacity of the cell. This model argues that for the regulation of RP, Tor and PKA genes converge to act at a late step, closer to the transcriptional activators of these genes. This convergence provides a molecular mechanism for coordinating the sensing of both nitrogen (via Tor) and carbon (via PKA) sources to appropriately drive growth in response to nutrients or restrain it in response to nutrient limitation. By maintaining two separate pathways, the cell also ensures a high fidelity of signal transmission and allows each pathway to individually govern other cellular responses and to coordinate their signal transmission with other global regulatory networks.

Given the relevance of Tor and the cAMP-PKA pathways to growth control in yeast, nematodes, flies, and humans, it is not surprising that these pathways are perturbed in a vast number of human malignancies (recently reviewed in references 3 and 58). Understanding the interplay between Tor and other signal transduction cascades furthers knowledge of the molecular events that transpire during the transformation of normal cells to the malignant state and provides insight for clinical applications of rapamycin and its analogs as chemotherapeutic agents.


We thank Joseph Heitman and John Rohde for their continued support and encouragement and for critical reading of the manuscript. We thank Stephen Garrett, Xuewen Pan, and Toshiaki Harashima for strains.

This work was supported by grant CA94925-03 from the NCI (to M.E.C.).


1. Barbet, N. C., U. Schneider, S. B. Helliwell, I. Stansfield, M. F. Tuite, and M. N. Hall. 1996. TOR controls translation initiation and early G1 progression in yeast. Mol. Biol. Cell 7:25-42. [PMC free article] [PubMed]
2. Beck, T., and M. N. Hall. 1999. The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors. Nature 402:689-692. [PubMed]
3. Bjornsti, M. A., and P. J. Houghton. 2004. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4:335-348. [PubMed]
4. Broach, J. R. 1991. RAS genes in Saccharomyces cerevisiae: signal transduction in search of a pathway. Trends Genet. 7:28-33. [PubMed]
5. Cameron, S., L. Levin, M. Zoller, and M. Wigler. 1988. cAMP-independent control of sporulation, glycogen metabolism, and heat shock resistance in S. cerevisiae. Cell 53:555-566. [PubMed]
6. Cannon, J. F., and K. Tatchell. 1987. Characterization of Saccharomyces cerevisiae genes encoding subunits of cyclic AMP-dependent protein kinase. Mol. Cell. Biol. 7:2653-2663. [PMC free article] [PubMed]
7. Cardenas, M. E., N. S. Cutler, M. C. Lorenz, C. J. Di Como, and J. Heitman. 1999. The TOR signaling cascade regulates gene expression in response to nutrients. Genes Dev. 13:3271-3279. [PubMed]
8. Cardenas, M. E., and J. Heitman. 1995. FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity. EMBO J. 14:5892-5907. [PubMed]
9. Cherkasova, V. A., and A. G. Hinnebusch. 2003. Translational control by TOR and TAP42 through dephosphorylation of eIF2α kinase GCN2. Genes Dev. 17:859-872. [PubMed]
10. Cutler, N. S., X. Pan, J. Heitman, and M. E. Cardenas. 2001. The TOR signal transduction cascade controls cellular differentiation in response to nutrients. Mol. Biol. Cell 12:4103-4113. [PMC free article] [PubMed]
11. Duvel, K., A. Santhanam, S. Garrett, L. Schneper, and J. R. Broach. 2003. Multiple roles of Tap42 in mediating rapamycin-induced transcriptional changes in yeast. Mol. Cell 11:1467-1478. [PubMed]
12. Francois, J. M., S. Thompson-Jaeger, J. Skroch, U. Zellenka, W. Spevak, and K. Tatchell. 1992. GAC1 may encode a regulatory subunit for protein phosphatase type 1 in Saccharomyces cerevisiae. EMBO J. 11:87-96. [PubMed]
13. Garrett, S., and J. Broach. 1989. Loss of Ras activity in Saccharomyces cerevisiae is suppressed by disruptions of a new kinase gene, YAKI, whose product may act downstream of the cAMP-dependent protein kinase. Genes Dev. 3:1336-1348. [PubMed]
14. Gimeno, C. J., P. O. Ljungdahl, C. A. Styles, and G. R. Fink. 1992. Unipolar cell divisions in the yeast S. cerevisiae lead to filamentous growth: regulation by starvation and RAS. Cell 68:1077-1090. [PubMed]
15. Goldstein, A. L., and J. H. McCusker. 1999. Three new dominant drug resistance cassettes for gene disruption in Saccharomyces cerevisiae. Yeast 15:1541-1553. [PubMed]
16. Görner, W., E. Durchschlag, M. T. Martinez-Pastor, F. Estruch, G. Ammerer, B. Hamilton, H. Ruis, and C. Schüller. 1998. Nuclear localization of the C2H2 zinc finger protein Msn2p is regulated by stress and protein kinase A activity. Genes Dev. 12:586-597. [PubMed]
17. Görner, W., E. Durchschlag, J. Wolf, E. L. Brown, G. Ammerer, H. Ruis, and C. Schüller. 2002. Acute glucose starvation activates the nuclear localization signal of a stress-specific yeast transcription factor. EMBO J. 21:135-144. [PubMed]
18. Hafen, E. 2004. Interplay between growth factor and nutrient signaling: lessons from Drosophila TOR. Curr. Top. Microbiol. Immunol. 279:153-167. [PubMed]
19. Harashima, T., and J. Heitman. 2004. Nutrient control of dimorphic growth in Saccharomyces cerevisiae, p. 131-169. In J. G. Winderickx and P. M. Taylor (ed.), Topics in current genetics, vol. 7. Springer-Verlag, Berlin, Germany.
20. Hardwick, J. S., F. G. Kuruvilla, J. K. Tong, A. F. Shamji, and S. L. Schreiber. 1999. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc. Natl. Acad. Sci. USA 96:14866-14870. [PubMed]
21. Hardy, T. A., D. Huang, and P. J. Roach. 1994. Interactions between cAMP-dependent and SNF1 protein kinases in the control of glycogen accumulation in Saccharomyces cerevisiae. J. Biol. Chem. 269:27907-27913. [PubMed]
22. Heitman, J., N. R. Movva, and M. N. Hall. 1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905-909. [PubMed]
23. Jiang, Y., C. Davis, and J. R. Broach. 1998. Efficient transition to growth on fermentable carbon sources in Saccharomyces cerevisiae requires signaling through the Ras pathway. EMBO J. 17:6942-6951. [PubMed]
24. Klein, C., and K. Struhl. 1994. Protein kinase A mediates growth-regulated expression of yeast ribosomal protein genes by modulating RAP1 transcriptional activity. Mol. Cell. Biol. 14:1920-1928. [PMC free article] [PubMed]
25. Komeili, A., K. P. Wedaman, E. K. O'Shea, and T. Powers. 2000. Mechanism of metabolic control. Target of rapamycin signaling links nitrogen quality to the activity of the Rtg1 and Rtg3 transcription factors. J. Cell Biol. 151:863-878. [PMC free article] [PubMed]
26. Kubota, H., T. Obata, K. Ota, T. Sasaki, and T. Ito. 2003. Rapamycin-induced translational derepression of GCN4 mRNA involves a novel mechanism for activation of the eIF2α kinase GCN2. J. Biol. Chem. 278:20457-20460. [PubMed]
27. Kunz, J., R. Henriquez, U. Schneider, M. Deuter-Reinhard, N. R. Movva, and M. N. Hall. 1993. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 73:585-596. [PubMed]
28. Long, X., F. Muller, and J. Avruch. 2004. TOR action in mammalian cells and in Caenorhabditis elegans. Curr. Top. Microbiol. Immunol. 279:115-138. [PubMed]
29. Longtine, M. S., A. McKenzie III, D. J. Demarini, N. G. Shah, A. Wach, A. Brachat, P. Philippsen, and J. R. Pringle. 1998. Additional modules for versatile and economical PCR-based gene deletion and modification in Saccharomyces cerevisiae. Yeast 14:953-961. [PubMed]
30. Lorenz, M. C., and J. Heitman. 1997. Yeast pseudohyphal growth is regulated by GPA2, a G protein α homolog. EMBO J. 16:7008-7018. [PubMed]
31. Lorenz, M. C., X. Pan, T. Harashima, M. E. Cardenas, Y. Xue, J. P. Hirsch, and J. Heitman. 2000. The G protein-coupled receptor Gpr1 is a nutrient sensor that regulates pseudohyphal differentiation in Saccharomyces cerevisiae. Genetics 154:609-622. [PubMed]
32. Marbach, I., R. Licht, H. Frohnmeyer, and D. Engelberg. 2001. Gcn2 mediates Gcn4 activation in response to glucose stimulation or UV radiation not via GCN4 translation. J. Biol. Chem. 276:16944-16951. [PubMed]
33. Mbonyi, K., and J. M. Thevelein. 1988. The high-affinity glucose uptake system is not required for induction of the RAS-mediated cAMP signal by glucose in cells of the yeast Saccharomyces cerevisiae. Biochim. Biophys. Acta 971:223-226. [PubMed]
34. Neuman-Silberberg, F. S., S. Bhattacharya, and J. R. Broach. 1995. Nutrient availability and the RAS/cyclic AMP pathway both induce expression of ribosomal protein genes in Saccharomyces cerevisiae but by different mechanisms. Mol. Cell. Biol. 15:3187-3196. [PMC free article] [PubMed]
35. Pan, X., and J. Heitman. 1999. Cyclic AMP-dependent protein kinase regulates pseudohyphal differentiation in Saccharomyces cerevisiae. Mol. Cell. Biol. 19:4874-4887. [PMC free article] [PubMed]
36. Pedruzzi, I., F. Dubouloz, E. Cameroni, V. Wanke, J. Roosen, J. Winderickx, and C. De Virgilio. 2003. TOR and PKA signaling pathways converge on the protein kinase Rim15 to control entry into G0. Mol. Cell 12:1607-1613. [PubMed]
37. Powers, T., and P. Walter. 1999. Regulation of ribosome biogenesis by the rapamycin-sensitive TOR-signaling pathway in Saccharomyces cerevisiae. Mol. Biol. Cell 10:987-1000. [PMC free article] [PubMed]
38. Proud, C. G. 2004. Role of mTOR signalling in the control of translation initiation and elongation by nutrients. Curr. Top. Microbiol. Immunol. 279:215-244. [PubMed]
39. Reid, J. L., V. R. Iyer, P. O. Brown, and K. Struhl. 2000. Coordinate regulation of yeast ribosomal protein genes is associated with targeted recruitment of Esa1 histone acetylase. Mol. Cell 6:1297-1307. [PubMed]
40. Reinders, A., N. Burckert, T. Boller, A. Wiemken, and C. De Virgilio. 1998. Saccharomyces cerevisiae cAMP-dependent protein kinase controls entry into stationary phase through the Rim15p protein kinase. Genes Dev. 12:2943-2955. [PubMed]
41. Rohde, J., J. Heitman, and M. E. Cardenas. 2001. The TOR kinases link nutrient sensing to cell growth. J. Biol. Chem. 276:9583-9586. [PubMed]
42. Rohde, J. R., S. Campbell, S. A. Zurita-Martinez, N. S. Cutler, M. Ashe, and M. E. Cardenas. 2004. TOR controls transcriptional and translational programs via Sap-Sit4 protein phosphatase signaling effectors. Mol. Cell. Biol. 24:8332-8341. [PMC free article] [PubMed]
43. Rohde, J. R., and M. E. Cardenas. 2004. Nutrient signaling through TOR kinases controls gene expression and cellular differentiation in fungi. Curr. Top. Microbiol. Immunol. 279:53-72. [PubMed]
44. Rohde, J. R., and M. E. Cardenas. 2003. The Tor pathway regulates gene expression by linking nutrient sensing to histone acetylation. Mol. Cell. Biol. 23:629-635. [PMC free article] [PubMed]
45. Ruis, H., and C. Schüller. 1995. Stress signaling in yeast. Bioessays 17:959-965. [PubMed]
46. Schiestl, R. H., M. Dominska, and T. D. Petes. 1993. Transformation of Saccharomyces cerevisiae with nonhomologous DNA: illegitimate integration of transforming DNA into yeast chromosomes and in vivo ligation of transforming DNA to mitochondrial DNA sequences. Mol. Cell. Biol. 13:2697-2705. [PMC free article] [PubMed]
47. Schmelzle, T., T. Beck, D. E. Martin, and M. N. Hall. 2004. Activation of the RAS/cyclic AMP pathway suppresses a TOR deficiency in yeast. Mol. Cell. Biol. 24:338-351. [PMC free article] [PubMed]
48. Sherman, F. 2002. Getting started with yeast. Methods Enzymol. 350:3-41. [PubMed]
49. Sikorski, R. S., and P. Hieter. 1989. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122:19-27. [PubMed]
50. Smith, A., M. P. Ward, and S. Garrett. 1998. Yeast PKA represses Msn2p/Msn4p-dependent gene expression to regulate growth, stress response and glycogen accumulation. EMBO J. 17:3556-3564. [PubMed]
51. Stanhill, A., N. Schick, and D. Engelberg. 1999. The yeast ras/cyclic AMP pathway induces invasive growth by suppressing the cellular stress response. Mol. Cell. Biol. 19:7529-7538. [PMC free article] [PubMed]
52. Tanaka, K., B. K. Lin, D. R. Wood, and F. Tamanoi. 1991. IRA2, an upstream negative regulator of RAS in yeast, is a RAS GTPase-activating protein. Proc. Natl. Acad. Sci. USA 88:468-472. [PubMed]
53. Thevelein, J. M. 1994. Signal transduction in yeast. Yeast 10:1753-1790. [PubMed]
54. Toda, T., S. Cameron, P. Sass, and M. Wigler. 1988. SCH9, a gene of Saccharomyces cerevisiae that encodes a protein distinct from, but functionally and structurally related to, cAMP-dependent protein kinase catalytic subunits. Genes Dev. 2:517-527. [PubMed]
55. Toda, T., S. Cameron, P. Sass, M. Zoller, J. D. Scott, B. McMullen, M. Hurwitz, E. G. Krebs, and M. Wigler. 1987. Cloning and characterization of BCY1, a locus encoding a regulatory subunit of the cyclic AMP-dependent protein kinase in Saccharomyces cerevisiae. Mol. Cell. Biol. 7:1371-1377. [PMC free article] [PubMed]
56. Toda, T., S. Cameron, P. Sass, M. Zoller, and M. Wigler. 1987. Three different genes in S. cerevisiae encode the catalytic subunits of the cAMP-dependent protein kinase. Cell 50:277-287. [PubMed]
57. Toda, T., I. Uno, T. Ishikawa, S. Powers, T. Kataoka, D. Broek, S. Cameron, J. Broach, K. Matsumoto, and M. Wigler. 1985. In yeast, RAS proteins are controlling elements of adenylate cyclase. Cell 40:27-36. [PubMed]
58. Tortora, G., and F. Ciardiello. 2002. Protein kinase A as target for novel integrated strategies of cancer therapy. Ann. N. Y. Acad. Sci. 968:139-147. [PubMed]
59. Valenzuela, L., C. Aranda, and A. González. 2001. TOR modulates GCN4-dependent expression of genes turned on by nitrogen limitation. J. Bacteriol. 183:2331-2334. [PMC free article] [PubMed]
60. Ward, M. P., C. J. Gimeno, G. R. Fink, and S. Garrett. 1995. SOK2 may regulate cyclic AMP-dependent protein kinase-stimulated growth and pseudohyphal development by repressing transcription. Mol. Cell. Biol. 15:6854-6863. [PMC free article] [PubMed]
61. Warner, J. R. 1999. The economics of ribosome biosynthesis in yeast. Trends Biochem. Sci. 24:437-440. [PubMed]
62. Woolford, J. L., Jr. 1991. The structure and biogenesis of yeast ribosomes. Adv. Genet. 29:63-118. [PubMed]
63. Zaragoza, D., A. Ghavidel, J. Heitman, and M. C. Schultz. 1998. Rapamycin induces the G0 program of transcriptional repression in yeast by interfering with the TOR signaling pathway. Mol. Cell. Biol. 18:4463-4470. [PMC free article] [PubMed]

Articles from Eukaryotic Cell are provided here courtesy of American Society for Microbiology (ASM)